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Abstract: Visceral adipose tissue (VAT) is an important risk factor
for obesity-related metabolic disorders. Therefore, a reduction in
VAT has become a key goal in obesity management. However, VAT
is correlated with intrahepatic triglyceride (IHTG) content, so it is
possible that IHTG, not VAT, is a better marker of metabolic diseases.
We determined the independent association of IHTG and VAT to met-
abolic functions, by evaluating groups of obese subjects, who differed
in IHTG content (high or normal) but matched on VAT volume or dif-
fered in VAT volume (high or low) but matched on IHTG content. Sta-
ble isotope tracer techniques and the euglycemic–hyperinsulinemic
clamp procedure were used to assess insulin sensitivity and very-
low-density lipoprotein-triglyceride (VLDL-TG) secretion rate. Tissue
biopsies were obtained to evaluate cellular factors involved in ecto-
pic triglyceride accumulation. Hepatic, adipose tissue, and muscle
insulin sensitivities were 41%, 13%, and 36% lower (p <0.01), respec-
tively, whereas VLDL-triglyceride secretion rate was almost double
(p <0.001), in subjects with higher than normal IHTG content,
matched on VAT. No differences in insulin sensitivity or VLDL-TG
secretion were observed between subjects with different VAT vol-
umes, matched on IHTG content. Adipose tissue CD36 expression
was lower (p <0.05), whereas skeletal muscle CD36 expression was
higher (p <0.05), in subjects with higher than normal IHTG. These
data demonstrate that IHTG, not VAT, is a better marker of the met-
abolic derangements associated with obesity. Furthermore, altera-
tions in tissue fatty acid transport could be involved in the
pathogenesis of ectopic triglyceride accumulation by redirecting
plasma fatty acid uptake from adipose tissue toward other tissues.
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Bugianesi).Nonalcoholic fatty liver disease (NAFLD) is a chronic meta-
bolic disorder with signiﬁcant impact on overall mortality [1].
Although the gastroenterologist’s focus is mainly on its hepatic
complications, patients with NAFLD have a risk of cardiovascular
diseases highly exceeding the risk of liver-related deaths [2].
NAFLD has been proposed as the hepatic manifestation of the
metabolic syndrome (MetS), with insulin resistance (IR) as the
common pathophysiological mechanism [3]. The relationship
between NAFLD and MetS is bidirectional. Liver fat content is sig-
niﬁcantly increased in subjects with MetS as compared with
those without, independent of age, gender, and body mass index
(BMI); in turn, the presence of NAFLD is a strong predictor of
MetS, and markers of NAFLD are associated with the future risk
of Type 2 diabetes and cardiovascular mortality, i.e. the worri-
some outcomes of MetS [2,4].
The most recent deﬁnition of MetS by the International Diabe-
tes Federation [3] focuses on abdominal obesity as a necessary
feature, because it is thought to be ‘an early step in the aetiolog-
ical cascade leading to the full metabolic syndrome’, as demon-
strated by several epidemiological and clinical studies.
Nevertheless, each component of MetS is also associated with
increased liver fat content [5], and the relative role of abdominal
versus hepatic fat in the onset of MetS is a recent matter of
debate.
The article by Fabbrini et al. [6] signiﬁcantly adds to this
intriguing puzzle. The authors evaluated two groups of obese
patients. Subjects in each group were matched on age, sex, BMI,
and percentage of body fat, but differed in either intrahepatic tri-
glyceride (IHTG) content or visceral adipose tissue (VAT) volume.
The authors used state-of-the-art techniques (2-step hyperinsuli-
nemic–euglycemic clamp combined with stable isotope tracers)
to assess hepatic, skeletal muscle, and adipose tissue insulin sen-
sitivities and to evaluate VLDL-TG secretion rate. Compared with
subjects with low IHGT matched on VAT, subjects with high IHTG
content had a signiﬁcantly lower hepatic, adipose tissue, and
muscle insulin sensitivities (respectively reduced by 41, 13, and
36%; p <0.01) and a twofold increased VLDL-triglyceride secretion
rate (p <0.001). On the contrary, no differences in insulin sensitiv-
ity or VLDL-TG secretion were observed between subjects with
different VAT volumes, matched on IHTG content. The author’s
conclusion was that IHTG content, rather than VAT, is the main
determinant of insulin resistance at the whole-body level.
Some drawbacks in the presentation of data should be pointed
out. At ﬁrst glance, the impression is that only patients with
increased IHTG content display metabolic abnormalities, and
the lack of a control group considerably contributes to it. In a10 vol. 53 j 1146–1147
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previous study [7] using the same two-step clamp methodology,
total glucose disposal was stimulated 3-fold by insulin in non-
diabetic subjects with NAFLD, compared with 6-fold in matched
lean healthy controls. The insulin sensitivity index (reciprocal
of insulin resistance index) in the NAFLD group was, on average,
0.5. With the proviso that a direct comparison is inappropriate,
both patients matched for liver fat with high or low VAT, or
matched for intra-abdominal fat with high or low IHTG content,
had a degree of insulin-stimulated glucose disposal, and indices
of hepatic insulin sensitivity comparable to the NAFLD group
mentioned above, i.e. all of them were anyway signiﬁcantly insu-
lin resistant both in the liver and in the muscle. Nevertheless,
subjects with increased IHTG had further impairment in insulin
sensitivity at the whole-body level and, most signiﬁcantly,
secreted a signiﬁcantly higher amount of VLDL derived from
intrahepatic sources, i.e., lipolysis of intrahepatic triglyceride,
hepatic lipolysis of circulating triglyceride, and de novo hepatic
fatty acid synthesis.
Whether a fatty liver is the consequence or an active player in
the progression of insulin resistance is the ‘‘chicken or the egg”
tale, and cannot be discriminated by cross-sectional studies;
however, the liver is the major source of endogenously produced
glucose, and determines the plasma glucose concentration. Liver
fat has been shown to be closely associated with impaired insulin
inhibition of hepatic glucose production both in non-diabetic
subjects and in type 2 diabetic patients [5]. Analogous to fat in
the liver, increased intramyocellular triglyceride content closely
correlates with muscle IR and is a better predictor of impaired
insulin action than visceral adiposity [8].
Organ-speciﬁc deposition of fat is a strong predictor of insulin
resistance, as highlighted by inherited or highly active antiretro-
viral therapy (HAART)-related forms of lipodystrophy, where the
selective loss of subcutaneous and visceral fat is associated with
steatosis, hypertriglyceridemia, and severe IR [9]. On the other
hand, in patients with familial hypobetalipoproteinemia (FHBL),
which have high levels of IHTG because of a genetic defect in
hepatic export of triglycerides, insulin sensitivity in the liver
and in the muscle is comparable to healthy controls, suggesting
that fatty liver per se does not necessarily mean hepatic IR [10].
Similarly, gene variants of adiponutrin are associated with
increased IHTG but not with IR in the general population [11].
Of note, hepatic steatosis induced by reduced triglycerides clear-
ance, such as in genotype 3 chronic hepatitis C, appears less able
to induce IR, pointing out the importance of lipotoxicity from
increased free fatty acid (FFA) delivery rather than from triglycer-
ides, which might represent an inert form of fat accumulation
[12]. In this light, visceral fat can thus be considered the ﬁrst buf-
fer of lipotoxic FFA ﬂuxes, being a site less metabolically active
than the liver, even though mesenteric adipocytes are a crucial
source of FFAs entering portal circulation and providing the sub-
strates to increase gluconeogenesis and hepatic glucose produc-
tion [13].
Once ectopic fat accumulates in the liver, clinical conse-
quences will become more relevant in terms of impaired glucose
production, leading to increased probability of diabetes, and
altered lipid proﬁle, leading to atherosclerosis. Alternatively, sub-
jects who display a better ability to clear fat from the liver would
probably be those at lower risk of developing the complications
of MetS.
Finally, the comparison of relatively small groups of subjects
cannot provide meaningful quantitative estimates of the relativeJournal of Hepatology 2010contribution to MetS of the two fat depots, but the quantity of
liver fat has been shown to predict the presence of the typical
glucose and lipid metabolic disturbances of MetS independently
of VAT also in the large population of the Framingham Heart
Study [4]. In an another large study, both VAT and liver fat
explained variation in serum triglyceride, HDL cholesterol, and
insulin concentrations independently of each other, but liver fat
was the only predictor of fasting glucose levels [14].
In conclusion, because of its master function in the regulation
of glucose and lipid disposal, the liver should be considered as the
hepatic trigger of the MetS, rather than its target. In the future,
the presence of fatty liver as a strong predictor of cardiovascular
and metabolic complications should not be ignored in the
international guidelines for MetS. Prospective clinical studies
are warranted to evaluate whether the treatment of fatty liver
could be effective in the prevention of cardiovascular events.Conﬂict of interest
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